acid sensing ion channel subunit family member 4Genealiases: ACCN4 · BNAC4
Q-omics provides the consensus-scored ASIC4 profile across patient tissues and cancer cell-line models. ASIC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ASIC4 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ASIC4 RNA expression shows 15,915 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where ASIC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASIC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASIC4 survival associations across molecular data types. ASIC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASIC4 RNA expression–survival associations across cancer types. High ASIC4 expression shows unfavorable associations in MESO, KIRC, KIRP, LIHC and UVM, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ASIC4 RNA expression.
This table summarizes ASIC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASIC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASIC4 shows lower tumor expression in BLCA and higher tumor expression in HNSC, KIRC, CHOL, PAAD and COAD. The HNSC box plot shows higher ASIC4 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p < 0.001).
This table shows molecular features associated with ASIC4 in patient tissues and cancer cell lines. In patient samples, ASIC4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ASIC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
